Synergistic combination of menogarol and melphalan and other two drug combinations.
Menogarol is a new anthracycline undergoing phase I clinical trial. We report here the lethality after 2 hr exposure to 2 drug combinations of menogarol and several antitumor agents. A new statistical procedure was used to identify synergistic combinations. Most of these combinations were additive, except for menogarol plus melphalan, which was synergistic. Adriamycin plus melphalan was also synergistic. The menogarol-melphalan combination wa studied in detail with regard to the effect of dose and drug-schedule, lethality for exponential and plateau phase cells and effect on cell cycle progression. Although the combination was synergistic for exponential cells it was additive for plateau phase cells. The combination exerted a synergistic effect in inhibiting progression of cells through the cell cycle. After 2 hr menogarol exposure cells were blocked in G2 for about 12 hr following which the block was reversed. This reversal was inhibited when menogarol was combined with melphalan. The uptake of menogarol or melphalan was not changed in the presence of the other drug.
Bhuyan
B K
BK
Adams
E G
EG
Johnson
M
M
Crampton
S L
SL
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003630:Daunorubicin / Q000031:analogs & derivatives*; D004317:Doxorubicin / Q000008:administration & dosage / Q000494:pharmacology; D004357:Drug Synergism; D008545:Melanoma / Q000378:metabolism / Q000473:pathology*; D008558:Melphalan / Q000008:administration & dosage / Q000494:pharmacology*; D017290:Menogaril; D051379:Mice; D009621:Nogalamycin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology*
D004317:Doxorubicin; D017290:Menogaril; D009621:Nogalamycin; D008558:Melphalan; D003630:Daunorubicin